济川药业
(600566)
| 流通市值：265.29亿 | | | 总市值：267.02亿 |
| 流通股本：9.16亿 | | | 总股本：9.22亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,525,389,316.3 | 8,016,894,756.63 | 5,805,134,511.2 | 4,034,400,209.97 |
| 营业收入 | 1,525,389,316.3 | 8,016,894,756.63 | 5,805,134,511.2 | 4,034,400,209.97 |
| 二、营业总成本 | 1,106,091,598.54 | 5,388,666,480.38 | 3,879,965,357.38 | 2,717,305,015.54 |
| 营业成本 | 347,010,714.96 | 1,663,540,786.59 | 1,204,122,608.31 | 823,982,793.25 |
| 税金及附加 | 28,352,466.9 | 134,385,142.83 | 92,793,745.97 | 63,590,546.22 |
| 销售费用 | 557,671,736.88 | 2,954,132,882.49 | 2,190,344,923.91 | 1,610,143,804.25 |
| 管理费用 | 101,924,935.8 | 432,654,677.67 | 301,233,712 | 189,579,615.62 |
| 研发费用 | 100,945,084.37 | 444,781,764.51 | 296,861,461.95 | 208,204,374.23 |
| 财务费用 | -29,813,340.37 | -240,828,773.71 | -205,391,094.76 | -178,196,118.03 |
| 其中:利息费用 | 3,508,802.64 | 27,273,290.37 | 22,746,776.34 | 15,879,320.48 |
| 其中:利息收入 | 33,626,362.84 | 269,224,895.33 | 229,024,263.75 | 194,656,242.46 |
| 加:公允价值变动收益 | 11,969,723.03 | 99,202,006.27 | 86,459,260.4 | 51,999,388.12 |
| 加:投资收益 | 28,673,815.84 | 83,540,174.24 | 30,728,253.75 | 15,800,332 |
| 资产处置收益 | - | 197,641.88 | 188,213.44 | -4,733.85 |
| 资产减值损失(新) | 1,202.98 | -2,881,730.82 | - | - |
| 信用减值损失(新) | 37,363,496.91 | 22,258,137.62 | 51,746,773.19 | 49,799,886.79 |
| 其他收益 | 5,018,401.98 | 32,345,111 | 25,365,926.32 | 23,101,784.18 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 502,324,358.5 | 2,862,889,616.44 | 2,119,657,580.92 | 1,457,791,851.67 |
| 加:营业外收入 | 12,738,381.35 | 116,799,700.02 | 115,101,979.63 | 110,900,820.88 |
| 减:营业外支出 | 393,735.39 | 1,443,057.47 | 1,261,923.35 | 1,033,976.52 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 514,669,004.46 | 2,978,246,258.99 | 2,233,497,637.2 | 1,567,658,696.03 |
| 减:所得税费用 | 73,376,337.8 | 441,539,927.5 | 326,151,566.57 | 226,364,771.13 |
| 六、净利润 | 441,292,666.66 | 2,536,706,331.49 | 1,907,346,070.63 | 1,341,293,924.9 |
| 持续经营净利润 | 441,292,666.66 | 2,536,706,331.49 | 1,907,346,070.63 | 1,341,293,924.9 |
| 归属于母公司股东的净利润 | 440,335,904.83 | 2,531,554,060.02 | 1,902,829,554.86 | 1,338,306,956.4 |
| 少数股东损益 | 956,761.83 | 5,152,271.47 | 4,516,515.77 | 2,986,968.5 |
| (一)基本每股收益 | 0.48 | 2.76 | 2.07 | 1.45 |
| (二)稀释每股收益 | 0.48 | 2.76 | 2.07 | 1.45 |
| 九、综合收益总额 | 441,292,666.66 | 2,536,706,331.49 | 1,907,346,070.63 | 1,341,293,924.9 |
| 归属于母公司股东的综合收益总额 | 440,335,904.83 | 2,531,554,060.02 | 1,902,829,554.86 | 1,338,306,956.4 |
| 归属于少数股东的综合收益总额 | 956,761.83 | 5,152,271.47 | 4,516,515.77 | 2,986,968.5 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |